Emma Walmsley, GlaxoSmithKline CEO (Mandel Ngan/AFP via Getty Images)
GSK tangoes with private equity players to explore $54B sale of consumer unit instead of IPO — report
The spinout of GlaxoSmithKline’s consumer health unit could reportedly take the form of a $54 billion sale to private equity firms.
It would mark a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
